rolling inside the embryo. Might mesoderm gene expression be activated by structural cell deformation associated with this border? To answer this question, Brunet et al. injected the mechanically defective embryos with magnetic particles, allowing the margin cells to be mechnically towed by an electromagnet ring positioned around the embryo. Remarkably, this pro cedure rescued cell deformation, epiboly movements and mesoderm gene expression (Fig. 1c) . Furthermore, rescue occurred even in neighbouring cells that did not receive the magnetic particles, suggesting that mechanical forces are transmitted through cell-cell junctions.
Brunet et al. next studied Drosophila (fruitfly) embryos lacking the snail gene -these also show impaired mesoderm formation 6 . Again, they found that a mechanical challenge, in the form of external application of an indentation, restored mesoderm-formation competence in the embryos, suggesting that the relevance of mechanical interactions to this process is evolutionarily conserved.
Although Brunet and colleagues did not study the gastrulation mechanics of mammals and other amniotes, it is worth mentioning that in mouse and chick embryos epiboly seems to be uncoupled from mesoderm formation; instead, the latter occurs at a structure known as the primitive streak, which lies in the middle of the embryo 1 . However, at least in chick embryos, formation of the primitive streak is preceded by massive cell-cell intercalations, analogous to the epiboly movements in fish embryos. Intriguingly, interfering with these cellular movements in chick embryos does not block mesoderm formation, but causes it to form at the embryo boundary 7 , as in fish and other anamniotes. Thus, one might speculate that mesoderm induction in amniotes also requires an association with a mechanically challenged cellular state, as Brunet et al. predict . In line with this idea, it was recently shown 8 that, in mouse embryos, mechanical forces from maternal tissues have a causal role in forming the specialized tissue responsible for inducing the anteriorposterior axis.
So it seems that, after years of oblivion, research on mechanical forces is returning to centre stage in cell biology, promising to enhance our understanding of the links between cell behaviour and the structural context of cells and organs 9 . Such studies will also further our understanding of mechanotransduction pathways, which link physical forces to cell signalling. Brunet et al. contribute to this, by showing that the shuttling of the signalling molecule β-catenin from the cytoplasm to the nucleus can be used as a proxy for mechanical activation of border cells in the early phases of gastrulation in zebrafish and fly embryos. It seems that this nuclear shuttling occurs independently of the Wnt signalling pathway (with which β-catenin is typically associated), but instead involves phosphorylation of β-catenin by Src kinase enzymes. Clearly, further work is required to confirm the relevance of β-catenin as a mechano effector in gastrulation, given that some of the authors' claims about the function of this protein rest on experiments using overexpression of dominant-negative proteins.
Brunet and colleagues' work reminds us that cells can extract as much information from changes in their form or three-dimensional tissue localization as they do from soluble factors. How the genome responds to these changes, and whether the embryo uses mechanical forces as a long-range communication device to orchestrate its own morphogenesis, remain questions for future studies. A utophagy is a fundamental process in which a cell cannibalizes itself, degrading and recycling cytoplasmic proteins and organelles. This pathway has a crucial role in promoting cellular homeo stasis and survival in response to diverse forms of stress, so there is considerable interest in modulating autophagy in cancer cells. So far, clinical trials have focused predominantly on enhancing the efficacy of chemotherapy by inhibiting autophagy, using antimalarial drugs such as hydroxychloroquine 1 . But there is confusion as to whether inhibiting autophagy enhances or diminishes cancer therapy -current evidence suggests that both may be true. In this issue, Rosenfeldt et al. 2 (page 296) identify the tumour-suppressor protein p53 as a determinant of whether autophagy suppresses or accelerates the progression of pancreatic cancer.
Pancreatic cancers, specifically pancreatic ductal adenocarcinomas (PDACs), are aggressive and lethal tumours that commonly display mutational activation of the signalling molecule Kras 3 . Recent work has established that tumours characterized by mutations in Kras or other Ras proteins rely on autophagy for growth and cell proliferation, making this pathway an attractive therapeutic target [4] [5] [6] [7] . Rosenfeldt and colleagues used genetically engineered mice to investigate the role of autophagy in the progression and treatment of PDACs driven by the mutation Kras G12D . They demonstrate that silencing essential autophagy-regulating proteins (either ATG5 or ATG7) in Kras
G12D
-mutant pancreatic epithelial cells led to higher expression of p53, which was accompanied by decreased proliferation, increased apoptotic cell death and elevated cellular senescence, all of which are important barriers to tumour formation 8 . The authors further show that this loss of autophagy is sufficient to prevent the progression of early stage precancerous lesions, termed pancreatic intraepithelial neoplasias (PanINs), into more advanced cancers (Fig. 1a) . This finding is consistent with previous work demonstrating a requirement for autophagy in the growth of pancreatic cancer 9 . Interestingly, Rosenfeldt et al. also show that the engineered loss of autophagy in normal mouse pancreatic tissue led to elevated p53 expression and cell death, and that this resulted in pancreatic-tissue destruction and diabetes.
More than half of human PDACs exhibit silencing or mutation of the gene encoding p53 (ref. 10) , raising the question of whether defective autophagy will still prevent PDAC progression when p53 is inactivated. The authors tested the effects of combined autophagy loss and p53 deficiency in Krasmutant PDACs and, surprisingly, found that this accelerated, rather than impeded, PDAC progression (Fig. 1b) . In a key experiment, the authors treated mice that had Kras G12D -driven, p53-deficient lesions with hydroxychloroquine and again observed significantly faster PDAC formation. This result contrasts with the previous observation 9 of delayed tumour
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Tracking our neighbours' past
The collective motions of dwarf galaxies in planes around the Andromeda galaxy and the Milky Way have presented a challenge to theory. Interactions between galaxy groups in the distant past may have left their imprint on these dwarfs.
A L A N M C C O N N AC H I E
L ittle galaxies have long been known to orbit around large galaxies such as our own Milky Way or our neighbour Andromeda (Fig. 1) . But recent discoveries 1, 2 showing that the nearest 'dwarf ' galaxies are collectively rotating in giant planar structures -akin to disks -have baffled astronomers. Writing in Monthly Notices of the Royal Astronomical Society, Shaya and Tully 3 describe an analysis suggesting that the dwarfs' peculiar motion is an imprint of a time when Andromeda and the Milky Way were not the only big kids on the block. The same theory that has shown so much success in predicting the large-scale properties of the Universe -for example, the cosmic microwave background radiation that permeates the whole of space, detected in fine detail by the Planck satellite earlier this year 4 -also makes predictions about how dwarf galaxies progression following treatment of Kras G12D -driven, p53-normal PDACs with chloroquine, a hydroxychloroquine derivative.
Thus it seems that p53 acts as a switch in pancreatic cancer that dictates whether therapeutic inhibition of autophagy slows or accelerates disease progression. It remains unclear whether p53 similarly regulates autophagy inhibition in other cancers, but it seems likely that there will be cancer-specific nuancesin Kras-mutant lung cancers, for example, silencing of ATG7 suppresses proliferation and alters tumour differentiation, irrespective of p53 status 6 . Never theless, Rosenfeldt and colleagues' findings have immense clinical implications, because they highlight the importance of determining the p53 status of pancreatic cancers before treatment with autophagy inhibitors.
The activation of Ras proteins elicits profound metabolic changes that drive energy production and biosynthetic capacity in rapidly proliferating tumour cells; previous studies [4] [5] [6] [7] have demonstrated a requirement for autophagy in sustaining cellular metabolism during Ras mutation. In mouse models of lung cancers, autophagy-deficient precancerous tumours harbouring mutations in Kras or Braf (another signalling molecule commonly mutated in cancer) are unable to progress to the malignant stage and exhibit impaired mitochondrial metabolism 5, 6 . By contrast, Rosenfeldt et al. propose that increased glucose metabolism is responsible for the accelerated progression of Kras G12D -driven PDACs seen following concomitant inhibition of p53 and autophagy.
In support of this, the authors show that cells from PDACs growing in Kras G12D mice that also lacked p53 and ATG7 exhibited enhanced glucose uptake and increased metabolite levels compared with their autophagy-proficient Kras G12D , p53-lacking counterparts. However, restoration of autophagy by re-expression of ATG7 did not reverse these metabolic alterations, so it remains unclear whether the metabolic changes are a cause or a consequence of the increased aggressiveness displayed by PDAC cells lacking both autophagy and p53. Furthermore, the loss of autophagy may have other metabolic consequences: in Kras G12D -driven lung cancers, for example, the combined loss of ATG7 and p53 results in aberrant fatty-acid oxidation and profound lipid accumulation, suggesting a role for autophagy in lipid breakdown 5, 6 . Finally, it is important to recognize that in human Kras-mutant PDAC cell lines with p53 mutations, the loss of autophagy reduces proliferation and tumour growth 9 -the opposite effects to those described by Rosenfeldt et al. in mice. This discrepancy may arise from the different effects of p53 mutation versus outright genetic deletion on metabolism in pancreatic cancers. Although further study is required to understand the mechanism underlying the ability of p53 to switch the clinical outcome of autophagy inhibition, Rosenfeldt 
